Literature DB >> 19442595

Natural antibodies and cancer.

H Peter Vollmers1, Stephanie Brändlein.   

Abstract

The innate or natural immunity is the basis and key for all immune processes. Specific receptors on macrophages, dendrites, NK cells and natural antibodies producing B cells act as a first line defense and remove all 'foreign' and potentially harmful substances, that is, bacteria, viruses, cellular waste, modified molecules and, most importantly, cancer cells. Recognition and removal of transformed cells is a lifelong task of immune surveillance processes. Antibodies are hallmark components of this anti-cancer activity. To investigate their nature, specificity, and function, we used the human hybridoma technology for isolating antibodies from cancer patients. These were then tested with a panel of assays against cancer cell lines in vitro and in vivo. Interestingly, all the tumor-specific antibodies we found were germ-line coded and belonged nearly exclusively to the IgM class. Furthermore, they all bound to new carbohydrates on post-translationally modified cell surface receptors on malignant cells. So far no affinity maturated immunoglobulins detecting tumor-specific peptides were found. However, only the presentation of peptide motifs can create an immunological memory. In general malignant cells are detected at very early precursor stages and manifest tumors can be considered as exceptional events. In addition, malignant cells are neither infectious nor hide intracellularly like viruses and some bacteria. Therefore, it makes sense that anti-tumor immunity seems to be solely a part of the natural immunity and a memory is not needed and therefore not induced. This indicates that the tumor immunity seems to be restricted to innate immune mechanisms and the instruments used by nature, like natural antibodies, are obviously excellent therapeutics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19442595     DOI: 10.1016/j.nbt.2009.03.016

Source DB:  PubMed          Journal:  N Biotechnol        ISSN: 1871-6784            Impact factor:   5.079


  45 in total

1.  Characterization of an immunodominant cancer-specific O-glycopeptide epitope in murine podoplanin (OTS8).

Authors:  Catharina Steentoft; Katrine T Schjoldager; Emiliano Cló; Ulla Mandel; Steven B Levery; Johannes W Pedersen; Knud Jensen; Ola Blixt; Henrik Clausen
Journal:  Glycoconj J       Date:  2010-08-19       Impact factor: 2.916

Review 2.  Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.

Authors:  Bharath Wootla; Jens O Watzlawik; Nikolaos Stavropoulos; Nathan J Wittenberg; Harika Dasari; Murtada A Abdelrahim; John R Henley; Sang-Hyun Oh; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Opin Biol Ther       Date:  2016-03-10       Impact factor: 4.388

Review 3.  Harnessing benefit from targeting tumor associated carbohydrate antigens.

Authors:  Thomas Kieber-Emmons; Behjatolah Monzavi-Karbassi; Laura F Hutchins; Angela Pennisi; Issam Makhoul
Journal:  Hum Vaccin Immunother       Date:  2017-02       Impact factor: 3.452

Review 4.  Liver-spleen axis: intersection between immunity, infections and metabolism.

Authors:  Giovanni Tarantino; Antonella Scalera; Carmine Finelli
Journal:  World J Gastroenterol       Date:  2013-06-21       Impact factor: 5.742

Review 5.  Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.

Authors:  Jens O Watzlawik; Bharath Wootla; Meghan M Painter; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Rev Neurother       Date:  2013-09       Impact factor: 4.618

Review 6.  Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention.

Authors:  Camille Jacqueline; Olivera J Finn
Journal:  Semin Immunol       Date:  2020-04-06       Impact factor: 11.130

7.  Moving a Carbohydrate Mimetic Peptide into the clinic.

Authors:  Issam Makhoul; Laura Hutchins; Peter D Emanuel; Angela Pennisi; Eric Siegel; Fariba Jousheghany; Behjatolah Monzavi-Karbassi; Thomas Kieber-Emmons
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 8.  Bridging innate and adaptive antitumor immunity targeting glycans.

Authors:  Anastas Pashov; Bejatolah Monzavi-Karbassi; Gajendra P S Raghava; Thomas Kieber-Emmons
Journal:  J Biomed Biotechnol       Date:  2010-06-15

9.  A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency.

Authors:  Mariam Hammadi; Jacques-Olivier Pers; Christian Berthou; Pierre Youinou; Anne Bordron
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

10.  TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo.

Authors:  Xiuhong Piao; Tatsuhiko Ozawa; Hiroshi Hamana; Kiyomi Shitaoka; Aishun Jin; Hiroyuki Kishi; Atsushi Muraguchi
Journal:  Oncoimmunology       Date:  2016-05-04       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.